OrgUnit's Researchers
(Persons)

Results 1-5 of 9 (Search time: 0.005 seconds).

FullnameTranslated NameEmail
Buchanan, Russell R CRussell.Buchanan@austin.org.au
Hoi, Alberta YAlberta.HOI@austin.org.au
Lam, Simon K LSimon.LAM@austin.org.au
Leung, Jessica L YJessica.Leung@austin.org.au
Liew, David F LDavid.LIEW@austin.org.au

OrgUnit's Researchers publications
(Dept/Workgroup Publication)

Results 101-107 of 107 (Search time: 0.005 seconds).

Publication YearTitleAuthor(s)
101Feb-1994Unilateral scleroderma following ischemic hand injury.McColl, G; Buchanan, Russell R C 
1022022Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.Flores-Chávez, Alejandra; Brito-Zerón, Pilar; Retamozo, Soledad; Bitoun, Samuel; Fisher, Benjamin A; Liew, David F L ; Suijkerbuijk, Karijn; Chatzidionysiou, Katerina; Suárez-Almazor, María; Lambotte, Olivier; Mariette, Xavier; Ramos-Casals, Manuel; Liew, David 
10328-Apr-2021Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond.Liew, David F L ; Dau, Jonathan; Robinson, Philip C
104Feb-2016Variables associated with parent satisfaction with their child's pain management.Liversidge, Xien Lei; Taylor, David McD ; Liu, Bonnia ; Ling, Sophia Li-Yiing; Taylor, Simone Elise
105Feb-2022Waiting for JAK inhibitor safety data.Kragstrup, Tue Wenzel; Glintborg, Bente; Svensson, Annemarie L; McMaster, Christopher ; Robinson, Philip C; Deleuran, Bent; Liew, David F L 
10615-Nov-2021What does endemic COVID-19 mean for the future of rituximab?Liew, David F L ; Robinson, Philip C
10714-Feb-2009What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?Fajri, Dessy W; Brand, Caroline A; Dharmage, Shyamali C; Martin, Belinda J; Buchanan, Russell R C ; Schachna, Lionel